FTRE
Fortrea Holdings Inc.
NASDAQ · Healthcare · Biotechnology · US
$17.70
−4.94%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
18.7x
EV/EBITDA
32.4x
Market Cap
$1.68B
MomentumView details →
1D Return
−4.94%
YTD Return
+5.80%
RSI (14)
49.4
ValuationView details →
P/E (Fwd)
18.7x
EV/EBITDA
32.4x
Market Cap
$1.68B
RSI (14)
49.4
MomentumView details →
1D Return
−4.94%
YTD Return
+5.80%
SummaryUpdated Jun 1, 2026
Fortrea Holdings Inc. (NYSE:FTRE) is a contract research organization (CRO) that was spun off from Laboratory Corporation of America Holdings (LabCorp) in July 2023. The company was incorporated in 2023 and is headquartered in Durham, North Carolina. As a newly independent public company, Fortrea provides comprehensive clinical research services to pharmaceutical, biotechnology, and medical device companies worldwide, helping them navigate the complex process of bringing new treatments and medical devices to market.
Similar companies
Latest newsMore news →
Fortrea agreed to acquire the clinical pharmacology unit and bioanalytical laboratory operations from Worldwide Clinical Trials, adding dedicated bioanalytical capabilities and expanded capacity to Fortrea's early clinical development network.3d agoFortrea Holdings Inc. appointed David Smith as Interim Chief Financial Officer and principal financial officer, effective July 27, 2026.38d ago